Novel gene therapy for DMD induces expression of full-length dystrophin

A novel gene therapy may induce full-length dystrophin expression in patients with Duchenne muscular dystrophy (DMD), according to preliminary results from an ongoing clinical trial.

The therapy is an exon-skipping therapy targeting exon 2, the most commonly duplicated exon in the DMD gene, according to Dr Megan Waldrop of Nationwide Children’s Hospital in Columbus, Ohio, USA.

In a first-in-human trial, Dr Waldrop and colleagues assessed the effects of the gene therapy in patients with DMD. Treatment included intravenous administration of a viral vector (scAAV9.U7-ACCA) containing small nuclear RNA constructs that target the splice donor and acceptor domains of exon 2.

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.